The study is a single-centre, open-label, fixed-sequence, self-controlled clinical trial. It is planned to enroll 20 healthy adult subjects. Subjects will take SHR2150 on Day 1 and Day 21, and take efavirenz from Day 7 to Day 26.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
20
SHR2150 tablet single dose, Efavirenz single dose.
The People's Hospital of Liaoning Province
Shenyang, Liaoning, China
Tmax
Time to maximum observed serum concentration (Tmax) for SHR2150 after Single dose
Time frame: from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose
Cmax
Maximum observed serum concentration (Cmax) for SHR2150 after Single dose
Time frame: from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose
AUC0-t
Area under the plasma concentration versus time curve (AUC0-t) for SHR2150 after Single dose
Time frame: from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose
AUC0-inf
Area under the plasma concentration versus time curve (AUC0-inf ) for SHR2150 after Single dose
Time frame: from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose
T1/2
Time to elimination half-life (T1/2) for for SHR2150 after Single dose
Time frame: from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose
Number of subjects with adverse events and the severity of adverse events
Time frame: from Day 1 to Day 37 after the first dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.